SCHEMBL5360911

SCHEMBL5360911

NC(=O)C1CCN(S(=O)(=O)CCc2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
CYP2C19 P33261 2/20 0.56
ALDH1A1 P00352 4/20 0.53
NPSR1 Q6W5P4 2/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
PKM P14618 2/20 0.50
MMP1 P03956 1/20 0.50
MMP7 P09237 1/20 0.50
MMP8 P22894 1/20 0.50
MMP12 P39900 1/20 0.50
MMP13 P45452 1/20 0.50
FAAH O00519 1/20 0.49
TSHR P16473 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368854 0.86 MEN1 (0.61) LMNACYP2C19ALDH1A1HPGDSMN1; SMN2
SCHEMBL3939129 0.86 NPSR1 (0.69) LMNAALDH1A1NPSR1MAPTHPGD
Hydrochloric Acid SCHEMBL5015202 0.84 NPSR1 (0.67) LMNAALDH1A1NPSR1MAPTHPGD
SCHEMBL30728596 0.82 LMNA (0.63) LMNACYP2C19ALDH1A1NPSR1MAPT
SCHEMBL5352124 0.80 LMNA (0.60) LMNACYP2C19ALDH1A1SMN1; SMN2MMP1
SCHEMBL5367392 0.77 HTR2A (0.71) ALDH1A1PKMGAA
SCHEMBL20240865 0.75 ALDH1A1 (0.72) LMNAALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL4428781 0.75 LMNA (0.58) LMNAALDH1A1NPSR1MAPTHPGD
SCHEMBL4558491 0.74 RORC (0.57) CYP2C19ALDH1A1NPSR1SMN1; SMN2PKM
SCHEMBL5369479 0.74 POLB (0.78) CYP2C19ALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259157-B2 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK & CO., INC. (US) 2007-08-21 US disclosed
EP-1390034-A4 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2005-07-13 EP disclosed
US-20040204341-A1 Nr2b receptor antagonists for the treatment or prevention of migraines ALLEN CHRISTOPHER (US) 2004-10-14 US disclosed
EP-1390034-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-02-25 EP disclosed
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2003-06-26 US disclosed
WO-2002080928-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204341-A1 Nr2b receptor antagonists for the treatment or prevention of migraines HTR1B, HTR2B, HTR1A LMNA 1404/4885CYP2C19 1069/4885ALDH1A1 941/4885
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists GRIN1, GRIN2B, GRIN2A LMNA 4716/4885CYP2C19 2019/4885ALDH1A1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.